Oxygenta Pharmaceutical Ltd
Incorporated in 1990, Oxygenta Pharmaceutical Ltd manufactures Bulk Drugs and API including Pharmaceutical preparation, and Organic Fine Chemicals.
- Market Cap ₹ 236 Cr.
- Current Price ₹ 63.8
- High / Low ₹ 82.3 / 43.0
- Stock P/E
- Book Value ₹ -11.5
- Dividend Yield 0.00 %
- ROCE -33.6 %
- ROE %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
- Company's median sales growth is 22.1% of last 10 years
Cons
- Company has low interest coverage ratio.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6 | 12 | 8 | 13 | 21 | 14 | 52 | 61 | 31 | 40 | 109 | 113 | 135 | |
| 10 | 16 | 13 | 17 | 23 | 22 | 48 | 59 | 38 | 49 | 119 | 128 | 143 | |
| Operating Profit | -4 | -4 | -5 | -4 | -2 | -8 | 4 | 1 | -7 | -10 | -10 | -15 | -8 |
| OPM % | -67% | -34% | -59% | -31% | -10% | -57% | 7% | 2.4% | -23% | -24% | -9% | -14% | -6% |
| 0 | 0 | 1 | 1 | 0 | 4 | 2 | 1 | -1 | 0 | 1 | 0 | 0 | |
| Interest | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 2 | 5 | 7 |
| Depreciation | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 3 | 4 | 2 | 2 |
| Profit before tax | -7 | -6 | -6 | -4 | -3 | -6 | 3 | -0 | -11 | -14 | -14 | -22 | -17 |
| Tax % | -11% | 0% | 2% | 1% | -7% | -3% | 7% | 24% | 2% | -75% | -28% | -21% | |
| -6 | -6 | -6 | -5 | -3 | -6 | 3 | -1 | -12 | -3 | -10 | -18 | -14 | |
| EPS in Rs | -5.99 | -5.39 | -5.70 | -4.44 | -3.19 | -5.68 | 2.87 | -0.43 | -8.15 | -1.04 | -2.79 | -4.75 | -3.67 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 25% |
| 5 Years: | 17% |
| 3 Years: | 54% |
| TTM: | 21% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -28% |
| TTM: | 8% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 15% |
| 3 Years: | 24% |
| 1 Year: | -21% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 14 | 14 | 33 | 37 | 37 |
| Reserves | -26 | -32 | -38 | -42 | -45 | -51 | -48 | -49 | -60 | -54 | -63 | -80 |
| 15 | 17 | 19 | 19 | 22 | 27 | 48 | 52 | 68 | 57 | 62 | 110 | |
| 19 | 24 | 27 | 30 | 34 | 33 | 24 | 14 | 32 | 26 | 46 | 53 | |
| Total Liabilities | 18 | 20 | 19 | 17 | 21 | 19 | 34 | 31 | 54 | 63 | 83 | 120 |
| 12 | 13 | 12 | 12 | 12 | 11 | 16 | 20 | 28 | 29 | 37 | 48 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 6 | 7 | 6 | 5 | 9 | 7 | 17 | 11 | 26 | 34 | 46 | 72 | |
| Total Assets | 18 | 20 | 19 | 17 | 21 | 19 | 34 | 31 | 54 | 63 | 83 | 120 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4 | 1 | 1 | 1 | -8 | -3 | -2 | -2 | -2 | -13 | 3 | -28 | |
| 1 | -2 | -1 | -0 | -1 | -0 | -7 | -5 | -10 | -4 | -11 | -14 | |
| 3 | 1 | 0 | -1 | 8 | 3 | 9 | 6 | 11 | 17 | 8 | 43 | |
| Net Cash Flow | 0 | -0 | 0 | -0 | 0 | 0 | 0 | -0 | -0 | -0 | 0 | 0 |
| Free Cash Flow | -7 | -1 | -0 | 1 | -8 | -3 | -8 | -7 | -11 | -17 | -8 | -41 |
| CFO/OP | 104% | -20% | -13% | -33% | 396% | 35% | -37% | -106% | 23% | 135% | -29% | 182% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 38 | 44 | 39 | 14 | 9 | 11 | 11 | 10 | 120 | 68 | 17 | 32 |
| Inventory Days | 84 | 41 | 122 | 57 | 121 | 100 | 121 | 56 | 178 | 149 | 78 | 105 |
| Days Payable | 1,800 | 667 | 599 | 396 | 203 | 190 | 137 | 50 | 362 | 249 | 113 | 174 |
| Cash Conversion Cycle | -1,678 | -582 | -439 | -325 | -73 | -79 | -5 | 16 | -64 | -32 | -18 | -37 |
| Working Capital Days | -616 | -454 | -512 | -438 | -164 | -275 | -14 | 8 | -94 | -89 | -184 | -119 |
| ROCE % | -1% | -47% | -42% | -33% | -34% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Permanent Employees count |
|
|||||||||
| Coal Consumption MT |
||||||||||
| Power Consumption Lakhs Units |
||||||||||
Extracted by Screener AI
Documents
Announcements
- Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
- Shareholder Meeting / Postal Ballot-Outcome of AGM
-
Newspaper Advertisement
- Newspaper publication of notice for Oxygenta Pharmaceutical’s 33rd AGM on 31.07.2026.
-
Intimation Of Book Closure And Cut-Off Date For The 33Rd Annual General Meeting Of Oxygenta Pharmaceutical Limited.
- Book closure from 15-21 August 2026; AGM on 21 August 2026, with 14 August 2026 cut-off for e-voting.
-
Reg. 34 (1) Annual Report.
- 33rd annual report filed; AGM on 21 Aug 2026, with director appointments and related-party approvals proposed.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
BusinessOverview[1]
Oxygenta Pharmaceutical Limited (formerly
S.S. Organics Limited) is a Telangana-based manufacturer of pharmaceutical APIs and intermediates. The company operates one pharmaceutical segment and is a 56.5%-
owned subsidiary of unlisted Virupaksha Organics Limited